Viatris Achieves Major Regulatory Wins: FDA Clears Generic Injectable, Greenlights Contraceptive Patch Review

Healthcare company Viatris Inc. (VTRS) marked significant progress across its global product pipeline, securing multiple regulatory approvals and acceptances that span rare disease treatments to women’s health solutions.

Generic Injectable Medication Gets FDA Greenlight

The company’s octreotide acetate for injectable suspension—a generic version of the branded Sandostatin LAR Depot—has received FDA approval. This long-acting injectable represents Viatris’ fourth injectable approval this year, joining approvals for iron sucrose, paclitaxel, and liposomal amphotericin B. The medication is designed to manage symptoms of acromegaly and other rare conditions affecting the endocrine system.

Contraceptive Patch Advances in FDA Review Process

A more significant milestone for women’s health emerged when the FDA accepted Viatris’ New Drug Application for a novel low-dose estrogen transdermal patch for contraception. The weekly patch delivers 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol—a combination designed for women seeking noninvasive, reversible birth control options. The FDA assigned a target decision date of July 30, 2026. The patch is intended for women of childbearing age with a BMI below 30 kg/m² who are suitable candidates for hormone-based contraception. This represents a potential new choice in the contraceptive landscape for patients preferring convenient transdermal delivery over daily oral pills.

Gene Therapy for Rare Eye Disease Enters Clinical Development

The investigational application for MR-146, an Enriched Tear Film adeno-associated virus gene therapy candidate, cleared FDA review barriers. This treatment targets neurotrophic keratopathy (NK), a progressive corneal disease affecting approximately 73,000 Americans. NK can gradually damage vision and pose sight-threatening risks. Viatris announced plans to initiate the CORVITA Phase 1/2 clinical trial during the first half of 2026, representing an important advancement for patients with limited treatment options.

Sleep Disorder Treatment Gains Japanese Regulatory Traction

The Japan Pharmaceuticals and Medical Devices Agency accepted Viatris’ new drug application for pitolisant to treat obstructive sleep apnea syndrome (OSAS). The submission comes backed by positive Phase 3 trial data in Japanese patients. In the 12-week study, patients on pitolisant showed meaningful reductions in daytime sleepiness—as measured by the Epworth Sleepiness Scale—compared to placebo, with statistical significance (p=0.007). The benefit emerged even in patients already receiving CPAP therapy but experiencing residual excessive daytime sleepiness. Viatris intends to file another application for pitolisant in narcolepsy treatment by year-end.

Stock Performance Reflects Market Reaction

In early trading, VTRS shares moved to $11.66 on Nasdaq, representing a slight 0.34% decline. The regulatory developments underscore Viatris’ strategy of expanding across multiple therapeutic areas, from rare diseases to common health conditions affecting millions globally.